DSAP1; P100; RP11-13G14; TIP110; p110; p110(nrb)

For Research Use Only. Not for use in diagnostic procedures.

Polyclonal

IgG

Rabbit

Affinity Purification

Store at -20 degree C. Avoid freeze/thaw cycles.

Small volumes of anti-SART3 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

The protein encoded by this gene is an RNA-binding nuclear protein that is a tumor-rejection antigen. This antigen possesses tumor epitopes capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes in cancer patients and may be useful for specific immunotherapy. This gene product is found to be an important cellular factor for HIV-1 gene expression and viral replication. It also associates transiently with U6 and U4/U6 snRNPs during the recycling phase of the spliceosome cycle. This encoded protein is thought to be involved in the regulation of mRNA splicing.

Primary antibody

Western Blot (WB)

WB: 1:500 - 1:2000

Western blot analysis of extracts of various cell lines, using SART3 antibody at 1:3000 dilution.
Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (MBS128200) at 1:10000 dilution.
Lysates/proteins: 25ug per lane.
Blocking buffer: 3% nonfat dry milk in TBST.
Detection: ECL Basic Kit.
Exposure time: 30s.

110kDa

squamous cell carcinoma antigen recognized by T-cells 3

squamous cell carcinoma antigen recognized by T-cells 3

Squamous cell carcinoma antigen recognized by T-cells 3

Tip110??[Similar Products]

The protein encoded by this gene is an RNA-binding nuclear protein that is a tumor-rejection antigen. This antigen possesses tumor epitopes capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes in cancer patients and may be useful for specific immunotherapy. This gene product is found to be an important cellular factor for HIV-1 gene expression and viral replication. It also associates transiently with U6 and U4/U6 snRNPs during the recycling phase of the spliceosome cycle. This encoded protein is thought to be involved in the regulation of mRNA splicing. [provided by RefSeq, Jul 2008]

SART3: a ubiquitously expressed protein in proliferating cells. A component of the 7SK snRNP complex composed of P-TEFb (composed of CDK9 and CCNT1), HEXIM1, HEXIM2, BCDIN3, SART3 proteins and 7SK and U6 snRNAs. Transiently associates with the U6 and U4/U6 snRNPs during the spliceosome cycle, helping to regenerate functional U4/U6 snRNPs complexes. Expressed in the nucleus of all of malignant tumor cell lines tested and the majority of cancer tissues with various histologies, including squamous cell carcinomas, adenocarcinomas, melanomas and leukemias. However, this protein is undetectable in the nucleus of nonmalignant cell lines or normal tissues, except for the testis. Expressed in the cytoplasm of all proliferating cells, including normal and malignant cells, but not in most cells of normal tissues, except for the testis and the fetal liver. Regulates Tat transactivation activity through direct interaction. May be a cellular factor for HIV-1 gene expression and viral replication. 3 isoforms of the human protein are produced by alternative splicing.

Protein type: Nuclear receptor co-regulator; RNA-binding; Transcription regulation

Chromosomal Location of Human Ortholog: 12q23.3

Cellular Component: Cajal body; nucleoplasm; nucleus; U4/U6 x U5 tri-snRNP complex

Molecular Function: histone binding; protein binding; RNA binding; U4 snRNA binding; U6 snRNA binding; U6atac snRNA binding

Biological Process: assembly of spliceosomal tri-snRNP; nuclear mRNA splicing, via spliceosome; nucleosome assembly; regulation of gene expression; spliceosomal snRNP biogenesis

Disease: Porokeratosis 3, Disseminated Superficial Actinic Type

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.